Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.
[primary hyperoxaluria type 1]
Primary
hyperoxaluria
type
I
(
PH
I
)
is
caused
by
deficiency
of
the
liver
-
specific
enzyme
alanine-glyoxylate
:
aminotransferase
(
AGT
)
.
Many
mutations
are
known
to
perturb
AGT
protein
folding
.
Vitamin
B
6
(
B
6
)
is
the
only
specific
drug
available
for
treatment
.
Although
B
6
has
been
used
for
>
40
years
,
controlled
data
on
B
6
efficacy
are
lacking
.
Therefore
,
this
study
investigated
the
absolute
and
relative
change
of
urinary
oxalate
(
Uox
)
excretion
under
increasing
dosages
of
B
6
,
the
first
prospective
trial
to
do
so
.
B
6
response
was
studied
in
12
patients
(
7
male
patients
)
with
genetically
confirmed
PH
I
(
3
Gly
170
Arg
homozygous
,
5
compound
Gly
170
Arg
and
/
or
Phe
152
I
le
heterozygous
,
and
4
negative
for
Gly
170
A
rg
and
/
or
Phe
152
I
le
mutations
)
and
noncompromised
renal
function
.
Efficacy
was
defined
as
a
30
%
relative
reduction
in
Uox
excretion
.
B
6
was
administered
orally
starting
at
5
mg
/
kg
body
weight
per
day
and
given
in
increments
of
5
mg
/
kg
every
6
weeks
,
up
to
a
final
dosage
of
20
mg
/
kg
per
day
at
week
24
.
Uox
and
serum
B
6
levels
were
measured
every
6
weeks
.
Mean
relative
Uox
reduction
was
25
.
5
%
.
Uox
declined
from
2
.
09
±
0
.
55
(
mean
±
SD
)
at
baseline
to
1
.
52
±
0
.
60
mmol
/
1
.
73
m
(
2
)
per
day
(
P
=
0
.
01
)
at
week
24
.
Serum
B
6
levels
increased
from
22
.
5
±
8
.
7
to
1217
±
776
ng
/
ml
(
P
<
0
.
001
)
.
Six
patients
showed
a
≥
30
%
relative
reduction
of
Uox
at
week
24
.
This
first
prospective
trial
confirmed
B
6
efficacy
in
50
%
of
patients
(
three
of
three
homozygous
,
one
of
five
heterozygous
,
and
two
of
four
patients
negative
for
the
Gly
170
A
rg
and
/
or
Phe
152
I
le
mutations
)
.
Interestingly
,
no
complete
biochemical
remission
was
observed
,
even
in
the
homozygous
Gly
170
Arg
study
participants
.
Future
trials
are
necessary
to
learn
more
about
genotype-related
B
6
response
and
B
6
metabolism
.
Diseases
Validation
Diseases presenting
"phe152ile mutations"
symptom
primary hyperoxaluria type 1
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom